REG - Allergy Therapeutics - Result of Annual General Meeting

Allergy TherapeuticsAnnouncement

29/01/2026 14:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260129:nRSc9694Qa&default-theme=true

RNS Number : 9694Q  Allergy Therapeutics PLC  29 January 2026

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Result of Annual General Meeting

 

 

29 January 2026 - Allergy Therapeutics plc (AIM:AGY), the fully commercial
biotechnology company specialising in allergy immunotherapies, announces that
all resolutions proposed at the 2026 Annual General Meeting ("AGM") held today
were duly passed by shareholders on a show of hands.

 

Resolutions 1 to 10 (inclusive), were proposed as ordinary resolutions and
resolutions 11 to 13 (inclusive) were proposed as special resolutions. The
results of the proxy votes received ahead of the meeting are outlined in the
table below.

 

 

 Resolution                                                                     For:           %       Against:    %      Total Votes Cast  % of ISC  Withheld
 1. Approval of 2025 Accounts                                                   5,820,380,278  99.99%  755,751     0.01%  5,821,136,029     94.78%    56,047
 2. Approval of Directors'                                                      5,820,138,203  99.99%  836,062     0.01%  5,820,974,265     94.78%    217,811

 Remuneration Report
 3. To elect Helge Weiner-Trapness as a Director                                5,818,973,760  99.99%  141,507     0.01%  5,819,115,267     94.75%    2,076,809
 4. To elect Lawrence Allen Wang as a Director                                  5,818,962,852  99.99%  130,779     0.01%  5,819,093,631     94.75%    2,098,445
 5. To re-elect Tunde Otulana as a Director                                     5,818,680,380  99.99%  418,353     0.01%  5,819,098,733     94.75%    2,093,343
 6. To re-elect Cheryl MacDiarmid as a Director                                 5,818,939,949  99.99%  157,006     0.01%  5,819,096,955     94.75%    2,095,121
 7. To re-elect Peter Jensen O.B.E. as a Director                               5,804,855,547  99.76%  14,246,551  0.24%  5,819,102,098     94.75%    2,089,978
 8. To re-appoint BDO LLP as auditors of the Company                            5,818,732,937  99.99%  126,888     0.01%  5,818,859,825     94.75%    2,332,251
 9. To authorise the Directors to agree the auditors' remuneration              5,820,969,519  99.99%  134,889     0.01%  5,821,104,408     94.78%    87,668
 10. Authority to allot shares                                                  5,820,919,431  99.99%  179,941     0.01%  5,821,099,372     94.78%    92,704
 11. Special Resolution: Subject to the passing of Resolution 10, to authorise  5,817,602,998  99.94%  3,509,576   0.06%  5,821,112,574     94.78%    79,502
 the Directors to allot equity securities
 12. Special Resolution: Subject to the passing of Resolution 10, to authorise  5,817,696,087  99.94%  3,419,851   0.06%  5,821,115,938     94.78%    76,138
 the Directors, in addition to any authority granted under Resolution 11, to
 allot equity securities
 13. Special Resolution: To amend the Articles of Association                   5,818,896,008  99.99%  198,676     0.01%  5,819,094,684     94.75%    2,097,392

 

 

 

- ENDS -

 

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

 

ICR Healthcare

 

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com
(mailto:allergytherapeutics@icrhealthcare.com)

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the potential to
cure disease. The Group sells proprietary and third-party products from its
subsidiaries and branches in nine major European countries and via
distribution agreements in an additional four countries. For more information,
please see www.allergytherapeutics.com (http://www.allergytherapeutics.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGAKCBDQBKDBDB



            Copyright 2019 Regulatory News Service, all rights reserved